Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy
Alkermes plc reported interim results from a long-term extension study of alixorexton in adults with narcolepsy type 1 and type 2. At week 24, alixorexton showed sustained improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with mean MWT sleep latency about 29 minutes (NT1) and 18 minutes (NT2) and mean ESS about 7.5 (NT1) and 8.9 (NT2). No serious treatment-emergent adverse events were reported.
How this was made
The 30-second read
Why it matters
The interim week-24 long-term extension analysis reports sustained improvements in wakefulness (MWT) and sleepiness (ESS) plus maintained patient-reported cognition and fatigue, with no serious treatment-emergent adverse events reported as of the May 12, 2026 cutoff.
Market read
For traders, the actionable signal is durability of wakefulness and sleepiness improvements through about nine months, alongside a reassuring interim safety profile, which can strengthen expectations for upcoming Phase 3 readouts.
What to watch
Key missing items for trading conviction include effect size versus placebo at week 24, discontinuation reasons, and whether cognition/fatigue improvements are clinically meaningful across all subgroups.
Background
Alkermes is evaluating alixorexton (an investigational oral orexin-2 receptor agonist) in Phase 3 Brilliance studies for narcolepsy type 1 and type 2, with additional Phase 2 work in idiopathic hypersomnia.
Ticker impact
Alkermes reported interim week-24 long-term extension results for alixorexton, showing sustained MWT and ESS improvements and no serious TEAEs.
Moderate positive bias for ALKS sentiment, with limited immediate repricing until Phase 3 readouts or controlled comparative data.
The article provides specific week-24 efficacy metrics (MWT, ESS) and safety (no serious TEAEs) across NT1 and NT2, but it is an interim analysis from an open-label extension, reducing certainty versus randomized Phase 3 outcomes.
Market effects
Reinforces the orexin-2 agonist efficacy and durability thesis in hypersomnolence, potentially improving risk appetite for similar CNS sleep assets.
Primarily US-listed biotech sentiment; limited direct regional macro linkage.
Narcolepsy treatment efficacy signals can influence global CNS sleep competitive positioning, though impact is company-specific and interim.
Counterpoint
Open-label extension durability can overstate benefit versus placebo-controlled settings; safety and efficacy may not translate cleanly into Phase 3 endpoints.
Key entities
- companyAlkermes plc
Sponsor of the alixorexton long-term extension interim analysis in narcolepsy (NT1 and NT2).
- drugalixorexton
Investigational oral selective orexin-2 receptor agonist evaluated across narcolepsy and idiopathic hypersomnia studies.